浏览全部资源
扫码关注微信
1.中国航天科工集团七三一医院药学部,北京 100074
2.中国航天科工集团 七三一医院胸外科,北京 100074
3.北京医院药学部,北京 100730
主管药师,博士。研究方向:循证医学与医学信息学、指南和共识的制作与评价、抗肿瘤药物管理。E-mail:zhenglis1270755@163.com
副主任药师,博士。研究方向:老年慢病管理、药物警戒与合理用药、指南和共识的制作与评价。E-mail:sxl1220@163.com
纸质出版日期:2023-12-30,
收稿日期:2023-07-21,
修回日期:2023-11-01,
扫 描 看 全 文
郑丽,张凯华,孙雪林.弥漫大B细胞淋巴瘤治疗新药格菲妥单抗 Δ[J].中国药房,2023,34(24):3064-3067.
ZHENG Li,ZHANG Kaihua,SUN Xuelin.Glofitamab for diffuse large B cell lymphoma[J].ZHONGGUO YAOFANG,2023,34(24):3064-3067.
郑丽,张凯华,孙雪林.弥漫大B细胞淋巴瘤治疗新药格菲妥单抗 Δ[J].中国药房,2023,34(24):3064-3067. DOI: 10.6039/j.issn.1001-0408.2023.24.20.
ZHENG Li,ZHANG Kaihua,SUN Xuelin.Glofitamab for diffuse large B cell lymphoma[J].ZHONGGUO YAOFANG,2023,34(24):3064-3067. DOI: 10.6039/j.issn.1001-0408.2023.24.20.
弥漫大B细胞淋巴瘤(DLBCL)是一种来源于成熟B细胞的恶性肿瘤,目前其临床治疗以化学治疗为主,但仍有部分患者会在治疗后复发或进展为难治性DLBCL。2023年6月15日,美国FDA批准抗CD3/CD20双特异性单克隆抗体格菲妥单抗上市,为既往接受过二线或二线以上系统治疗后复发或进展为难治性DLBCL的患者提供了新的治疗方案。本文对格菲妥单抗的药理作用、临床研究、安全性及用法用量等进行了简要概述。格菲妥单抗主要通过促进T细胞的活化和增殖,激活T细胞释放肿瘤细胞杀伤蛋白,进而介导B细胞的裂解而发挥治疗DLBCL的作用。临床研究显示,格菲妥单抗对复发或难治性DLBCL具有较好的完全缓解率和客观缓解率,其常见不良反应包括轻/中度细胞因子释放综合征、肌肉骨骼疼痛、皮疹和疲劳,未见明显的药物相互作用。
Diffuse large B cell lymphoma (DLBCL) is a malignant tumor derived from mature B cells. Currently, chemotherapy is still the main clinical treatment. However, some patients experience recurrence or refractory conditions after treatment. On June 15, 2023, the FDA approved the marketing of glofitamab, a CD3/CD20 bispecific monoclonal antibody, to provide the new treatment plan for patients with recurrent or refractory DLBCL after receiving 2-line or above systemic treatment. This article reviews pharmacological effects, clinical studies, safety, usage and dosage of glofitamab. Glofitamab mainly plays a therapeutic role in DLBCL by promoting the activation and proliferation of T cells,activating T cells to release tumor cell-killing proteins, and mediating the lysis of B cells. Clinical studies have shown that glofitamab has a better complete and objective response rate for recurrent or refractory DLBCL. Common adverse reactions caused by glofitamab include mild/moderate cytokine release syndrome, musculoskeletal pain, rash, fatigue, and so on,without significant drug interactions.
格菲妥单抗弥漫大B细胞淋巴瘤抗CD3/CD20双特异性单克隆抗体药理作用临床研究安全性
diffuse large B cell lymphomaCD3/CD20 bispecific monoclonal antibodypharmacological effectsclinical studysafety
DUNLEAVY K,ERDMANN T,LENZ G. Targeting the B-cell receptor pathway in diffuse large B-cell lymphoma[J]. Cancer Treat Rev,2018,65:41-46.
佟丹江. 弥漫大B细胞淋巴瘤的流行病学分析[J]. 中国现代药物应用,2016,10(8):46-47.
TONG D J. Epidemiological analysis of diffuse large B-cell lymphoma[J]. Chin J Mod Drug Appl,2016,10(8):46-47.
SEHN L H,GASCOYNE R D. Diffuse large B-cell lymphoma:optimizing outcome in the context of clinical and biologic heterogeneity[J]. Blood,2015,125(1):22-32.
GOLDFINGER M,COOPER D L. lenalidomide in DLBCL:are we past the cell of origin?[J]. Clin Adv Hematol Oncol,2021,19(5):320-325.
MINSON A,DICKINSON M. Glofitamab CD20-TCB bispecific antibody[J]. Leuk Lymphoma,2021,62(13):3098-3108.
SUROWKA M,SCHAEFER W,KLEIN C. Ten years in the making:application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins[J]. mAbs,2021,13(1):1967714.
CREMASCO F,MENIETTI E,SPEZIALE D,et al. Cross-linking of T cell to B cell lymphoma by the T cell bispecific antibody CD20-TCB induces IFNγ/CXCL10-dependent peripheral T cell recruitment in humanized murine model[J]. PLoS One,2021,16(1):e0241091.
FDA. Glofitamab-gxbm(Columvi) prescribing information[EB/OL].(2023-06-15)[2023-07-21]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761309s000lbl.pdfhttps://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761309s000lbl.pdf.
DICKINSON M J,CARLO-STELLA C,MORSCHHAUSER F,et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma[J]. N Engl J Med,2022,387(24):2220-2231.
SONG Y Q,ZHANG H L,HUANG H Q,et al. Glo-fitamab monotherapy demonstrates high complete response rates and manageable safety in Chinese patients with relapsed or refractory diffuse large B-cell lymphoma and ≥2 prior therapies[J]. Blood,2022,140(supplement 1):12050-12051.
HUTCHINGS M,SUREDA A,TEROL M J,et al. Glofi-tamab(glofit)in combination with polatuzumab vedotin(pola):phase Ⅰb/Ⅱ preliminary data support manageable safety and encouraging efficacy in relapsed/refractory(R/R)diffuse large B-cell lymphoma(DLBCL)[J]. Blood,2021,138(Supplement 1):525.
TOPP M S,TANI M,DICKINSON M,et al. Glofitamab plus R-CHOP induces high response rates and a favorable safety profile in patients with previously untreated diffuse large B-cell lymphoma(DLBCL):results from a phase Ⅰb study[J]. Blood,2022,140(Supplement 1):1775-1777.
GUST J,HAY K A,HANAFI L A,et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells[J]. Cancer Discov, 2017,7(12):1404-1419.
MAUDE S L,FREY N,SHAW P A,et al. Chimeric antigen receptor T cells for sustained remissions in leukemia[J]. N Engl J Med, 2014,371(16):1507-1517.
BACAC M,COLOMBETTI S,HERTER S,et al. CD20-TCB with obinutuzumab pretreatment as next-generation treatment of hematologic malignancies[J]. Clin Cancer Res,2018,24(19):4785-4797.
SANCHEZ-PAULETE A R,LABIANO S,RODRIGUEZ-RUIZ M E,et al. Deciphering CD137(4-1BB)signaling in T-cell costimulation for translation into successful cancer immunotherapy[J]. Eur J Immunol,2016,46(3):513-522.
0
浏览量
5
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构